Recent advance in the discovery of allosteric inhibitors binding to the AMP site of fructose-1,6-bisphosphatase / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1291-1300, 2011.
Artigo
em Chinês
| WPRIM
| ID: wpr-232995
ABSTRACT
Fructose-1, 6-bisphosphatase (FBPase), a rate-limiting enzyme involved in the pathway of gluconeogenesis, can catalyze the hydrolysis of fructose-1, 6-bisphosphate to fructose-6-phosphate. Upon inhibiting the activity of FBPase, the production of endogenous glucose can be decreased and the level of blood glucose lowered. Therefore, inhibitors of FBPase are expected to be novel potential therapeutics for the treatment of type II diabetes. Recent research efforts were reviewed in the field of developing allosteric inhibitors interacting with the AMP binding site of FBPase.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Farmacologia
/
Sítios de Ligação
/
Sangue
/
Glicemia
/
Monofosfato de Adenosina
/
Química
/
Frutose-Bifosfatase
/
Diabetes Mellitus Tipo 2
/
Inibidores Enzimáticos
/
Sítio Alostérico
Limite:
Animais
/
Humanos
Idioma:
Chinês
Revista:
Acta Pharmaceutica Sinica
Ano de publicação:
2011
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS